Adashek JJ - Search Results

1

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma.

Zhang Y, Kumar P, Adashek JJ, Skelton WP 4th, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Zhang Y, et al. Among authors: adashek jj. Cells. 2022 Aug 12;11(16):2505. doi: 10.3390/cells11162505. Cells. 2022. PMID: 36010582 Free PMC article.

2

Adjuvant treatment in renal cell carcinoma.

Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Dizman N, et al. Among authors: adashek jj. Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Clin Adv Hematol Oncol. 2018. PMID: 30148828 Review.

3

Updates in the molecular epidemiology and systemic approaches to penile cancer.

Adashek JJ, Necchi A, Spiess PE. Adashek JJ, et al. Urol Oncol. 2019 Jul;37(7):403-408. doi: 10.1016/j.urolonc.2019.04.012. Epub 2019 May 1. Urol Oncol. 2019. PMID: 31053523 Review.

4

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.

Adashek JJ, Jain RK, Zhang J. Adashek JJ, et al. Cells. 2019 Aug 9;8(8):860. doi: 10.3390/cells8080860. Cells. 2019. PMID: 31404966 Free PMC article. Review.

5

Extramammary Paget's disease: what do we know and how do we treat?

Adashek JJ, Leonard A, Nealon SW, Krishnan A, Mosiello GC, Dhillon J, Spiess PE. Adashek JJ, et al. Can J Urol. 2019 Dec;26(6):10012-10021. Can J Urol. 2019. PMID: 31860417 Free article. Review.

6

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Adashek JJ, et al. Oncologist. 2020 Feb;25(2):94-98. doi: 10.1634/theoncologist.2019-0636. Epub 2019 Nov 20. Oncologist. 2020. PMID: 32043794 Free PMC article.

7

Understanding genomics and the immune environment of penile cancer to improve therapy.

Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Aydin AM, et al. Among authors: adashek jj. Nat Rev Urol. 2020 Oct;17(10):555-570. doi: 10.1038/s41585-020-0359-z. Epub 2020 Aug 18. Nat Rev Urol. 2020. PMID: 32812000 Review.

8

Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?

Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Adashek JJ, et al. Front Oncol. 2021 Feb 10;10:627025. doi: 10.3389/fonc.2020.627025. eCollection 2020. Front Oncol. 2021. PMID: 33643921 Free PMC article.

9

Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.

Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Chadha J, et al. Among authors: adashek jj. Clin Genitourin Cancer. 2022 Apr;20(2):e158-e165. doi: 10.1016/j.clgc.2021.12.002. Epub 2021 Dec 10. Clin Genitourin Cancer. 2022. PMID: 34974985 Free PMC article.

10

First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?

Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. Adashek JJ, et al. Drugs. 2022 Mar;82(4):439-453. doi: 10.1007/s40265-022-01683-6. Epub 2022 Feb 17. Drugs. 2022. PMID: 35175588 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters